New Delhi, Dec. 7 -- The Indian Pharmacopoeia Commission (IPC) has issued a cautionary notice regarding the safety of the pain reliever Meftal, commonly used for menstrual cramps and rheumatoid arthritis, according to a report in the media.

The advisory asks healthcare professionals and patients to actively monitor for any negative reactions associated with the drug.

In case of encountering such reactions, the advisory recommends reporting the issue to the national coordination center of the Pharmacovigilance Programme of India (PvPI) through the commission's website,, or using the Android mobile apps ADR PvPI, it added.

The IPC functions as an independent body under the Ministry of Health. It plays a crucial role in est...